Structure–function relationships in the neurotrophin family
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The study of structure–function relationships in the neurotrophin family has in recent years increased our understanding of several important aspects of neurotrophin function. Site‐directed mutagenesis studies have localized amino acid residues important for binding to the low‐affinity (p75 LNGFR), as well as to the members of the Trk family of tyrosine kinase receptors. A cluster of positively charged residues has been shown to form a surface for binding to p75 LNGFR in all four neurotrophins. Differences in the spatial distribution of these charges among the different neurotrophins may explain some of their distinct binding properties. Elimination of these positive charges drastically reduces binding to P75 LNGFR but not to the Trk family members, and it does not impair the biological properties of the neurotrophins in vitro, arguing that binding to and activation of Trk receptors is sufficient to mediate the biological responses of neurotrophins. In contrast. the binding sites to Trk receptors appear to be formed by discontinuous stretches of amino acid residues distributed throughout the primary sequence of the molecule. These include the N‐terminus, some of the variable loop regions and a β‐strand. Despite their apparent distribution, when viewed in the three‐dimensional structure of NGF, these residues appear grouped on one side of the neurotrophin dimer, delineating a continuous surface extending approximately parallel to the twofold symmetry axis of the molecule. Two symmetrical surfaces are formed along the axis of the neurotrophin dimer providing a model for ligand‐mediated receptor dimerization. In the neurotrophin family, co‐evolution of cognate ligands and Trk receptors has developed specific contacts through different residues in the same variable regions of the neurotrophins. Thus, binding specificity is determined by the cooperation of distinct active and inhibitory binding determinants that restrict ligand‐receptors interactions. Binding determinants to the Trk receptors can be manipulated independently in a rational fashion to create neurotrophin analogues with novel ligand‐binding properties. In this way, second‐generation chimeric neurotrophins with multiple specificities (pan‐neurotrophins) have been engineered which may have valuable applications in the treatment of neurodegeneration and nerve damage. 1994 John Wiley & Sons, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hohn, A., Leibrock, J., Bailey, K., & Barde, Y.-A. (1990) · Nature · doi:10.1038/344339a0 · Cited by 1,145
Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958
The changing scene of neurotrophic factors
Thoenen, H. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90097-e · Cited by 820
Cited by
Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284
Conner, J. M., Lauterborn, J. C., Yan, Q., Gall, C. M., & Varon, S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-07-02295.1997 · Cited by 1,097
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Metadata
- Authors
- Ibáñez, C. F.
- Venue
- Journal of Neurobiology
- Publisher
- Wiley
- Published
- 1994-11
- Volume
- 25
- Issue
- 11
- Pages
- 1349-1361
- ISSN
- 0022-3034 (ISSN-L)
- 1097-4695
- OpenAlex
- W2146441148
- Cited by
- 83
- References
- 3
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.